Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;38(12):e14696.
doi: 10.1111/dme.14696. Epub 2021 Sep 29.

Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes

Danijela Tatovic  1 , Colin M Dayan  1
Affiliations
Review

Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes

Danijela Tatovic et al. Diabet Med. 2021 Dec.

Abstract

For almost a hundred years, the management of Type 1 diabetes has not advanced beyond insulin replacement. However, insulin does not provide satisfactory glycaemic control in the majority of individuals and there remains a major unmet need for novel treatments for Type 1 diabetes. Immunomodulation to preserve beta-cell function offers the prospect of making treatment with insulin easier and/or preventing the need for insulin, particularly when it comes to novel low-risk immunotherapies. Led by the concept that the best insulin-producing cell is a patient's own beta-cell, the Type 1 diabetes scientific community has a challenging task ahead-to fundamentally change the management of this devastating disease by using low-risk immunotherapy to preserve endogenous beta-cell function and make metabolic control substantially easier. In that way, insulin and/or beta-cell replacement (stem cell or transplantation) should in the future be considered rescue therapies reserved for delayed presentations.

Keywords: Type 1 diabetes; immunotherapy; insulin.

PubMed Disclaimer

References

REFERENCES

    1. Miller KM, Foster NC, Beck RW, et al. Current state of Type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971-978.
    1. McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32(8):1036-1050.
    1. Wasag DR, Gregory JW, Dayan C, Harvey JN, Brecon G. Excess all-cause mortality before age 30 in childhood onset Type 1 diabetes: data from the Brecon Group Cohort in Wales. Arch Dis Child. 2018;103(1):44-48.
    1. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic Type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974.
    1. Greenbaum C, Lord S, VanBuecken D. Emerging concepts on disease-modifying therapies in Type 1 diabetes. Curr Diab Rep. 2017;17(11):119.

MeSH terms

LinkOut - more resources